RxDoctor Payments Data

George Wu, MD

Cardiovascular Disease · Santa Monica, CANPI 1144227158

Payments from drug & device makers

$2,478in general payments, 2019–2025

Across 128 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$453
  • Amgen$428
  • E.r. Squibb & Sons, L.L.C.$250
  • Johnson & Johnson$229
  • Boehringer Ingelheim$147
  • Akcea Therapeutics, Inc.$122
  • plus $850 from 22 others

What the payments were for

  • Food & beverage$2,476100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,478 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$518,507
Medicare patients
1,006
Services billed
6,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis12$310,705
EliquisApixaban120$150,542
Repatha SureclickEvolocumab137$138,884
JardianceEmpagliflozin59$57,554
XareltoRivaroxaban27$34,757
Praluent PenAlirocumab33$26,534
VascepaIcosapent Ethyl28$22,607
EdarbiAzilsartan Medoxomil14$7,591
Rosuvastatin Calcium343$6,220
Ezetimibe184$5,957
Metoprolol Succinate250$4,651
Carvedilol ErCarvedilol Phosphate13$3,649
Valsartan127$3,200
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide38$2,588
Diltiazem 24hr Er (Cd)Diltiazem Hcl46$2,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$19$461,247132 claims
Boehringer IngelheimJardiance$147$57,55459 claims
Johnson & JohnsonXarelto$229$34,75727 claims
Arbor Pharmaceuticals, Inc.Edarbi$15$7,59114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →